Diabetes Drug Breakthrough: SGLT2 Inhibitors Found to Quell Heart Inflammation
SGLT2 inhibitors, a class of drugs originally engineered to manage type 2 diabetes by promoting glucose excretion through the kidneys, have emerged as a cornerstone in modern cardiovascular therapeutics. A pivotal clinical study recently published in the journal Circulation has provided robust evidence that these medications exert profound anti-inflammatory effects, effectively reducing markers associated with…
